Schrodinger is trading at $18.05, up +10.06% now, after August 5 earnings showed a substantial revenue and profitability improvement.
- Q2 revenue reached $58.9 million, beating estimates, while net income turned positive at $6.0 million.
- Annual contract value rose 27% to $29.6 million; drug-discovery guidance increased to $65 million–$75 million.
- The move is primarily earnings-driven, with Bunsen’s launch and collaboration milestones strengthening the growth narrative.